GSK is exploring in a big way in the emerging markets, firstly last month it signed an alliance with Dr Reddy's of India for marketing 100 branded products in the generic segment then secondly it went on to set up manufacturing plant in Singapore and china for production of H1N1 vaccine. Last but not the least it is venturing into Middle East market by buying Bristol-Myers Squibb's 11 branded generics drugs in Lebanon, Jordan, Syria, Libya and Yemen for $23.2 million.Its time for Sanofi and Astrazeneca to rethink for their portfolio.......
No comments:
Post a Comment